oncerned about the outcome of some pharmaceutical company mergers and acquisitions, federal antitrust regulators have initiated a new policy toward asset sales that legal experts say may limit the pool of potential buyers and change the calculus for certain deals.

In general, the agency scrutinizes a merger or acquisition that creates two potentially worrisome scenarios. In the first, the acquiring company might shelve a pipeline product, squelching choices for patients. In the other, the acquiring company develops the medicine, but then might control the market for that type of product, assuming it has sufficient market share, and start charging higher prices.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Pharmaceutical production
Drug Pricing

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.